Used in neuroscience and Alzheimer's disease research to quantify levels of amyloid precursor protein (APP) and its cleavage products, particularly β-amyloid peptides, in biological samples such as cerebrospinal fluid, cell lysates, and brain tissue extracts. Enables researchers to study APP processing pathways, evaluate the effects of potential therapeutic compounds on amyloid production, and investigate the molecular mechanisms underlying amyloid plaque formation. Commonly applied in preclinical studies, drug development, and biomarker validation for neurodegenerative disorders. Provides a sensitive and specific method for high-throughput screening in both basic research and pharmaceutical settings.